AzTrials
AzTrials

Lung Cancer, Hepatocellular CarcinomaNCT07284121

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

An observational study of Lung Cancer, Hepatocellular Carcinoma, run by Hoffmann-La Roche at 92 sites in 8 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Lung Cancer, Hepatocellular Carcinoma
What is being tested?
Atezolizumab
How many people
700 participants
Where
92 sitesin 8 countries
Study dates
15 Jul 2025to 31 Dec 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with PD-L1 expression of >= 50% on TC, participants diagnosed with metastatic NSCLC with PD-L1 expression of ≥ 50% on TC who have not received prior systemic therapy for metastatic disease, participants diagnosed with ES-SCLC who have not previously been treated, and participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy.

Who may be able to join

  • Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:
  • Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC
  • Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated
  • Extensive-stage small cell lung cancer (ES-SCLC) not previously treated
  • Advanced or unresectable HCC not previously treated with systemic therapy
  • Should not have received > 4 prior cycles of IV Atezolizumab

Who cannot join

  • Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling
  • Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label
  • Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program
  • Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life

Trial locations and contacts

92 sites in 8 countries. Contact the study team or a site near you to ask about taking part.

Reference Study ID Number: MO45893 https://forpatients.roche.com/ No attachments to email below. contact

888-662-6728 (U.S. and Canada)

global-roche-genentech-trials@gene.com

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry contact

92 sites in 8 countries

Spain33 sites, 33 recruiting

  • Complejo Hospitalario Universitario de Albacete

    Albacete, 02006

    Recruiting

  • Hospital Universitario Mancha Centro (Alcázar de San Juan);Servicio de digestivo

    Alcázar de San Juan, Ciudad REAL, 13600

    Recruiting

  • Hospital Universitario Mancha Centro (Alcázar de San Juan);Servicio de oncología

    Alcázar de San Juan, Ciudad REAL, 13600

    Recruiting

  • Hospital General de Alicante;servicio de digestivo

    Alicante, 03010

    Recruiting

  • Hospital General Univ. de Alicante

    Alicante, 3010

    Recruiting

  • Complejo Hospitalario Torrecardenas

    Almería, Almeria, 04009

    Recruiting

  • Hospital de Badajoz

    Badajoz, 06080

    Recruiting

  • Hospital de Cruces

    Barakaldo, Vizcaya, 48903

    Recruiting

  • Hospital Clinic I Provincial

    Barcelona, 08036

    Recruiting

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041

    Recruiting

  • Hospital de Cruces

    Bilbao, Vizcaya, 48903

    Recruiting

  • Hospital General de Ciudad Real

    Ciudad Real, 13005

    Recruiting

  • Hospital Universitario San Cecilio

    Granada, 18016

    Recruiting

  • Hospital General Universitario de Guadalajara

    Guadalajara, 19002

    Recruiting

  • Hospital Sant Joan de Deu de Manresa;Servicio oncologia

    Manresa, Barcelona, 08243

    Recruiting

  • Hospital General Universitario J.M Morales Meseguer

    Murcia, 30008

    Recruiting

  • Hospital Virgen de Arrixaca;servicio de digestivo

    Murcia, 30120

    Recruiting

  • Hospital Univ. Central de Asturias

    Oviedo, Principality of Asturias, 33006

    Recruiting

  • Hospital Univ. Central de Asturias

    Oviedo, Principality of Asturias, 33011

    Recruiting

  • Hospital Son Espases

    Palma de Mallorca, Balearic Islands, 7120

    Recruiting

  • Complejo Hospitalario de Pontevedra

    Pontevedra, 36002

    Recruiting

  • Hospital Universitario Puerto Real

    Puerto Real, Cadiz, 11510

    Recruiting

  • Hospital Universitari Sant Joan de Reus

    Reus, Tarragona, 43204

    Recruiting

  • Complejo Hospitalario Nuestra Señora de la Candelaria

    Santa Cruz de Tenerife, Tenerife, 38010

    Recruiting

  • Hospital Universitario de Canarias

    Santa Cruz de Tenerife, Tenerife, 38320

    Recruiting

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    Santiago de Compostela, LA Coruna, 15706

    Recruiting

  • Hospital Virgen del Rocio;Servicio de digestivo

    Seville, 41013

    Recruiting

  • Hospital de Toledo;Servicio de digestivo

    Toledo, 45007

    Recruiting

  • Hospital de Toledo;servicio de oncologia

    Toledo, 47007

    Recruiting

  • Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia

    Valencia, 46015

    Recruiting

  • Hospital Clinico Universitario de Valladolid

    Valladolid, 47003

    Recruiting

  • Hospital Clinico Universitario Valladolid

    Valladolid, 47005

    Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009

    Recruiting

Other trials in Spain

Italy22 sites, 22 recruiting

  • Ente Ecclesiastico Ospedale Generale Regionale F Miulli

    Acquaviva Delle Fonti, Piedmont, 70021

    Recruiting

  • Cliniche Gavazzeni SpA Humanitas Gavazzeni

    Bergamo, Lombardy, 24125

    Recruiting

  • Azienda Sanitaria Territoriale Pesaro Urbino (AST PU) - Ospedale Santa Croce;UOC Oncologia - Stabilimento di Fano

    Fano (PU), The Marches, 61032

    Recruiting

  • IRCCS AOU San Martino - IST

    Genoa, Liguria, 16132

    Recruiting

  • Presidio Ospedaliero Vito Fazzi

    Lecce, Apulia, 73044

    Recruiting

  • Ospedale dell'Angelo

    Mestre, Veneto, 30174

    Recruiting

  • Fondazione IRCCS Ospedale Maggiore Policlinico

    Milan, Lombardy, 20122

    Recruiting

  • Ospedale Maggiore Policlinico

    Milan, Lombardy, 20122

    Recruiting

  • Asst Santi Paolo E Carlo

    Milan, Lombardy, 20142

    Recruiting

  • Humanitas Istituto Clinico Catanese S.p.A

    Misterbianco (CT), Sicily, 95045

    Recruiting

  • A.O. Universitaria Policlinico Di Modena

    Modena, Emilia-Romagna, 41100

    Recruiting

  • AORN Ospedali dei Colli Ospedale Monaldi

    Naples, Campania, 80131

    Recruiting

  • Az. Osp. Cardarelli

    Naples, Campania, 80131

    Recruiting

  • A.O.U. Maggiore della Carità

    Novara, Piedmont, 28100

    Recruiting

  • A.O.U. Policlinico Paolo Giaccone

    Palermo, Sicily, 90100

    Recruiting

  • Casa di Cura La Maddalena

    Palermo, Sicily, 90146

    Recruiting

  • Ospedale Provinciale Santa Maria Delle Croci

    Ravenna, Emilia-Romagna, 48100

    Recruiting

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, 00168

    Recruiting

  • Università Campus Bio-Medico di Roma

    Rome, Lazio, 128

    Recruiting

  • Azienda Ospedaliero Universitaria Di Sassari

    Sassari, Sardinia, 07100

    Recruiting

  • Ospedale Santa Chiara

    Trento, Trentino-Alto Adige, 38100

    Recruiting

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Veneto, 37126

    Recruiting

Other trials in Italy

Romania9 sites, 9 recruiting

  • Spitalul Clinic de Urgenta Prof. Dr. Agrippa Ionescu

    Bucharest, 011356

    Recruiting

  • Institut Oncologic Prof. Dr. Alexandru Trestioreanu

    Bucharest, 022328

    Recruiting

  • Institutul Clinic Fundeni Bucuresti

    Bucharest, 022328

    Recruiting

  • Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. Octavian Fodor

    Cluj-Napoca, 400162

    Recruiting

  • Spitalul Clinic Jude?ean de Urgen?? Sfântul Apostol Andrei Galati;oncology

    Galati, 800578

    Recruiting

  • Institutul Regional de Oncologie Iasi

    Iași, 700483

    Recruiting

  • Spitalul Municipal Ploiesti

    Ploieşti, 107071

    Recruiting

  • Spitalul Judetean de Urgenta Satu Mare

    Satu Mare, 440055

    Recruiting

  • Oncomed SRL

    Timișoara, 300239

    Recruiting

Other trials in Romania

Bulgaria7 sites, 7 recruiting

  • Multiprofile Hospital for Active Treatment Uni Hospital

    Panagyurishte, 4500

    Recruiting

  • Complex Oncological Center-Ruse EOOD

    Rousse, 7000

    Recruiting

  • Tokuda Hospital

    Sofia, 1407

    Recruiting

  • UMHAT "Sv. Ivan Rilski", EAD

    Sofia, 1431

    Recruiting

  • UMHAT Tsaritsa Yoanna - ISUL

    Sofia, 1527

    Recruiting

  • MBAL Serdika EOOD

    Sofia, 1632

    Recruiting

  • MHAT SofiaMed

    Sofia, 1797

    Recruiting

Other trials in Bulgaria

Belgium6 sites, 6 recruiting

  • CHIREC

    Auderghem, 1160

    Recruiting

  • AZ Sint Lucas (Sint Lucas)

    Ghent, 9000

    Recruiting

  • CHU HELORA - Hôpital de la Louvière - Site Jolimont

    Haine-Saint-Paul, 7100

    Recruiting

  • CHC MontLégia

    Liège, 4000

    Recruiting

  • ZNA Jan Palfijn

    Merksem, 2170

    Recruiting

  • CHU UCL Mont-Godinne

    Mont-godinne, 5530

    Recruiting

Other trials in Belgium

Poland6 sites, 6 recruiting

  • Narodowy Instytut Onkologii - Panstwowy Instytut Badawczy, Oddzia? w Krakowie

    Krakow, 31-115

    Recruiting

  • Uniwersytecki Szpital Kliniczny nr 4 w Lublinie

    Lublin, 20-954

    Recruiting

  • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie

    Olsztyn, 10-357

    Recruiting

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu

    Poznan, 60-569

    Recruiting

  • Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka

    Słupsk, 76-200

    Recruiting

  • NU-MED Centrum Diagnostyki i Terapii Onkologicznej

    Tomaszów Mazowiecki, 97-200

    Recruiting

Other trials in Poland

United Kingdom5 sites, 5 recruiting

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B15 2TH

    Recruiting

  • Royal Surrey County Hospital

    Guildford, GU2 7XX

    Recruiting

  • Leeds Teaching Hosp NHS Trust

    Leeds, LS9 7TF

    Recruiting

  • James Cook University Hospital

    Middlesbrough, TS4 3BW

    Recruiting

  • James Paget University Hospitals NHS Foundation Trust

    Norfolk, NR31 6LA

    Recruiting

Other trials in United Kingdom

Austria4 sites, 4 recruiting

  • Landesklinikum Krems

    Krems, 3500

    Recruiting

  • Ordensklinikum Linz Elisabethinen

    Linz, 4020

    Recruiting

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, 1210

    Recruiting

  • Klinikum Wels-Grieskirchen

    Wels, 4600

    Recruiting

Other trials in Austria

About this study

Official title: A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Being tested
Atezolizumab
Medical subject headings
Lung Neoplasms, Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AtezolizumabDrug

    Also called Tecentriq

    Atezolizumab will be administered at the discretion of the treating physician and independently of participation in this study.

Study groups in NCT07284121
Study groupRoleWhat they receive
Cohort 1: Early Non-small Cell Lung Cancer (NSCLC)Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with Programmed Cell-Death Ligand 1 (PD-L1) expression of >= 50% on Tumor Cell (TC).
Receives: Drug: Atezolizumab
Cohort 2: Metastatic NSCLCParticipants diagnosed with metastatic NSCLC with PD-L1 expression of >= 50% on TC who have not received prior systemic therapy for metastatic disease.
Receives: Drug: Atezolizumab
Cohort 3: Extensive stage small cell lung cancer (ES-SCLC)Participants diagnosed with ES-SCLC who have not previously been treated.
Receives: Drug: Atezolizumab
Cohort 4: Hepatocellular Carcinoma (HCC)Participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy.
Receives: Drug: Atezolizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Therapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) Score

    Measured: At Cycle 2 and Cycle 3 (each cycle duration/length is 3 weeks)

Secondary outcomes (4)

  1. Overall Survival (OS)

    Measured: Index date up to approximately 3.5 years

  2. OS at 2 Years

    Measured: After Index date up to 2 years

  3. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) Score

    Measured: Baseline or Index date

  4. Percentage of Participants With Adverse Events

    Measured: Up to approximately 3.5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2025
  2. Study start15 Jul 2025
  3. Primary completion31 Mar 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
700 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07284121
Sponsor's protocol ID
MO45893
Status last verified
Oct 2026
First submitted
21 Nov 2025
Last updated
9 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Lung Cancer, Hepatocellular Carcinoma, run by Hoffmann-La Roche at 92 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 92 sites in Spain, Italy, Romania, Bulgaria, Belgium and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Reference Study ID Number: MO45893 https://forpatients.roche.com/ No attachments to email below. (888-662-6728 (U.S. and Canada), global-roche-genentech-trials@gene.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Therapy Administration Satisfaction Questionnaire Subcutaneous (TASQ-SC) Score (time frame: At Cycle 2 and Cycle 3 (each cycle duration/length is 3 weeks)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07284121.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in